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Summar 3'
Anti-human monoclonal antibodies were used to detect and quantify interleukins-1
and 2 and intcrleukin-2 receptor expression in peripheral blood mononuclear cells
from a rhesus monkey. Intcrleukin-1 production could be induced by phorbol esters
(PMA) and was potentiated by phytohcmagglutinin (PHA). Interleukin-2 secretion
could also be induced by the combination of PHA and PMA, but only weakly with
PHA alone, Interleukin-2 receptor expression was present in a subpopulation of
unstimulatcd lymphocytes and could bc enhanced by PHA or PMA. These data
show once again that the rhesus monkey immune system is cross-reactive with the
human one and that rhesus macaque could be a good model to study intcrleukin
therapy.
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As with other nonhuman primates, the rhcsus monkey (Macaca mulatta) demonstrates marked
similarities to humans in its anatomy and physiology (13) due to a close phylogenetlc relationship.
These similarities arc of importance for medical research in many disciplines such as immunology.
Thus, rhesus monkcys have been used for many years as a model for infectious diseases ( 16, 20,
22) and grafting (18). Moreover, the discovery of a simian immunodeficiency virus (SI V) capablc
of inducing an acquired immunodcficicncy syndrome (AIDS)-Iike disease in rhesus monkcys (4,
12) contributed to AIDS research (2, 7, 16). Interestingly, more and more cross-reactivity of
human immunological reagents has been described (16, 22), reinforcing the usefulness of this
animal model as a human analogue in the immunological field. An increasing number of anti-human
monoclonal antibodies (MAbs) against cell surface antigens can be used to determine lymphocyte
subsets in the rhesus monkey (14, 18, 21, 25). As a consequence, functional activities of
mononuclear cells from rhesus monkeys could be compared with humans ( 1, 9, 19).
In contrast, to our knowledge of cell membrane markers, little is known about cytokines or
cvtokine receptors in macaques (15), and especially rhesus monkeys (3, 8). lnterleukin-I beta (IL-
li is a multifunctional polypeptide which is secreted by monocytes and participates in T lymphocyte
blast transformation (26). lnterleukin-2 (IL-2) is produced by activated T lymphocytes and
participates in T lymphocyte proliferation once the interleukin-2 receptor (IL-2R) is expressed (26).
The present study was undertaken to determine whether IL-1, IL-2, and IL-2R expression could be
quantified in rhesus monkeys using anti-human MAbs.
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Materials and Methods
Animals and blo_xl samples. Rhesus monkeys (Macaca mulatta) of various ages, housed at
Centre d'Etudes ct de Recherche en M_decine A6rospatiale (Brdtigny sur Orge, France) and at
Centre de Primatologie (Niederhausbergen, France) were used in this study. Monkeys were housed
according to WHO criteria under the supervision of a veterinarian. Peripheral blood (5 ml) was
obtained by veinipunture from Ketamin ( 10 mg/kg) (Panpharma, Yvery/Seine, France) tranquilized
animals using heparinized sterile vacutainer tubes (Becton Dickinson, San Jose, CA). The _mples
were shipped by express mail at ambient temperature to the laborator T within 24 h after sampling.
Peripheral blood mononuclear cell isolation. Peripheral blood mononuclear cells (PBMC) were
separated on a density medium (MSL, Eurobio, Paris, France) by centrifugation for 25 rain at 400
g. The PBMC were then washed twice in RPMI 1640 medium (Gibco BRL, Cergy-Pontoise,
France) and resuspended at a concentration of 106 viable cells/ml of culture medium consisting of
RPMI 1640 supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, and 10% heat-
inactivcd fetal bovine serum (IBF, Villeuve-La-Garennc, France).
lnterleukin production and ELISA assays. Duplicate or triplicate cultures containing 2xlO -s
PBMC per well were set up in 0.2 ml of culture medium in U-bottom microtiter plates (Nunc,
Roskildc, Denmark) and incubated for 48 h in the prc_nce of activators in a 37"C, humidified, 5 %
COz atmosphere. The IL 2 production was induced by stimulating PBMC with various
concentrations (10 and 20 mg/I) of phytohemagglutinin-P (PHA-P, Sigma Chemical, St. Louis,
MO) or 10 mg/l PHA plus i or 5 ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma). The IL-
l secretion was induced by incubating the PBMC in the presence of 1, 5 or 10 ng/mi of PMA or
with 20 mg/l of PHA plus 1 ng/ml PMA. After incubation, the plates were centrifuged at 4OOxg for
10 rain and the supernatants were collected and stored at -800C until analysis. In order to minimize
inter-experimental variations, all the experiments were performed using the same batches of
reagents previously aliquoted and frozen. The ILl and IL2 were measured by a non commercial
enzyme immunoassays as previously described (5, 6). Secreted ILl was measured in cell
supcrnatants and total ILl was measured by lysing the cells with detergent in the culture wells (5).
Human recombinant ILl and IL2 (Biogen, Geneva, Switzerland) were used as standards. For
additional control experiments a sandwich immunoassay was used for both IL-I and IL-2
(Immunotcch, Marscillc, France).
Labeling of IL-2 receptor (IL-2R)-expressing cells. Cultured PBMC stimulated with 5 lttg/ml of
PHA or 1 and 5 ng/ml of PMA for 12, 24, 36, and 48 h were resuspended in .05 ml of PBS-
NAN3. Next, .005 ml of FITC-conjugated anti-lL-2R alpha chain monoclonal antibc-.xty (10) (anti-
CD25, hybridoma B 1.49.9, Immunotech, Marseille, France) were added for 15 min at 4"C. After
two washes in PBS-NaN3, the cells were fixed in PI3S containing 0.37 % formaldehyde and stored
at 4°C in the dark until analysis within a maximum of l day after labeling. In order to test the
specificity of our antibody monkey PBMC were stimulated with PHA (5ng/ml) for 36h and were
then incubated for lh at 4"C with 10 Ul/ml human recombinant IL2 (Biotest, Dreieich, Germany).
After two washes, half of the cells were incubated at 37"C for lh in order to enable the
internalization of the IL-2 receptor. The cells were then stained as described above.
Cytofluorometric analysis was carried out using a FACScan Analyser (13ecton-Dickinson) fitted
with a single laser and filters allowing detection of light emission of fluorescein. Forward scatter
and side scatter parameters were used to gate lymphocytes and monocytes and to gate out damaged
cells and debris. For each sample, the fluorescence intensities of 104 cells were recorded, and the
percentage of tx)sitive cells was computed through LYSYS II software (Becton-Dikinson).
Statistical Analysis. Measurements were compared to each other by means of a paired t test. Alpha
was set a priori at p < 0.05.
Result___.__s
IL-1 was produced by resting PBMC, and its production was significantly enhanced when
PBMC were triggered by PMA. Interestingly, as in humans, low doses of PHA potentiate
drastically the IL-1 secretion (Fig. l). The optimal concentration of PMA was 1 ng/ml (Fig. 2).
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FIG. 1
IL-1 secrclion in rhesus monkey PBMC. IL-1 secretion by PBMC was quantified
in either unstimulatcd cells or in cclls that received PMA (5 ng/ml) or PMA (1
ng/rnl) plus PHA (20 mg/I) -stimulated cclls for 48 h. Rcsults arc cxprcsscd as
mcan _ SD, n = 5.
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FIG. 2
IL-1 secretion in rhesus monkey PBMC. IL-1 secretion was induced in PBMC
with various concentrations of PMA over a 24 h pericxl. IL- 1 concentrations
decreased slightly when PBMC were stimulated with PMA concentrations higher
than 1 ng/ml. Rcsults are expressed as mean ± SD, n = 5.
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FIG. 3
IL-2R expression in rhesus monkey PBMC. IL-2R expression in unstimulated
and PMA (5 ng/ml) or PHA (5 mg/I of PHA) -stimulated cells was determined by
cytofluorimetry. Thc IL-2R was cxpresscd on unstimulated T lymphocytes (IL-
2R+ cells) and is increased in PHA (5 mg/l) stimulated cells. Results arc
cxprcsscd as mean __+SD, n = 5.
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FIG. 4
IL-2R expression in rhesus monkey PBMC. IL-2R expression in PMA (5 ng/ml)
-stimulated cells was determined by cytofluorimetry. The percentage of IL-2R
positive cells reached a maximum after 36 h.
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TABLEI
IL-2 (U/ml) SD
Control 0 0
PHA 0 0
PMA .03 .025
PHA + PMA ,62 ,24
IL-2 secretion in rhesus monkey PBMC. IL2 secretion (U/mi) by PBMC was
undetectable in unstimulated or in PHA (10 rag/i) stimulated cells. A detectable
amount of IL2 was produced when PMA (5 ng/ml) was used as the activator
whereas, PHA (10 rag/l) largely potentiated the effect of the same concentration of
PMA. Results are expressed as mean ± SD, n = 7.
TABLEII
IL-2 (U/ml)
Monkey Control PHA + PMA
1 0 2.30
2 .23 4.96
3 0 .52
4 .15 2.19
5 .26 .52
IL-2 secretion in rhesus monkcy PBMC. In this experiment, IL2 secretion (U/ml)
was dctcctablc in some monkcys in unstimulated cells. IL2 production was
incrcascd whcn PBMC wcrc stimulatcd with PMA (5 ng/ml) plus PHA ( 10 mg/l).
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IL-2 was nearly undctcctable in unstimulatcd or in PHA-stimulated PBMC. Similar to IL-1, IL-2
secretion was induccd by PMA and PHA potentiatcd strongly this activation (Table 1). No IL-2
was detectable with PHA alone in one cxperiment (Table 1) and, in another experiment, small
amounts of IL-2 were dctcctablc in unstimulatcd PBMC cultures in 3 animals out of 5 (Table II).
Thcse diffcrcnces might be duc to the diffcrcnt origin of thc monkeys or to inter-laboratory
variability bctx_ccn the cxpcriments. In ordcr to furthcr demonstate the cross-reactivity of anti-
human MAbs raiscd against IL-1 and IL-2, we also uscd successfully commercially availablc
sandwich immunoassays (data not shown).
In rcsting PBMC cultured for 48 h, approximatly 9 % of the T-lymphocytes expressed the IL-2R
(Fig. 3). Thc numbcr of IL-2R l:x)sitive cclls increases in presence of PHA and PMA (Fig. 3).
Similar to IL- 1 sccrction, the expression of the IL-2 R was at an optimum at 1 ng/ml of PMA. In
fact, the percentage of IL-2R positive cells was in the same range with I and 5 ng/ml of PMA (data
not shown). Thc time course of IL-2R expression showed a rapid increase in IL-2R positive cells
after 24 h of culture and reached a maximum after 48 h with PMA or PHA. The same results wherc
obtained with 5 ng/ml of PMA (Fig. 4) or with 5 mg/l of PHA (data not shown). The incubation of
PHA-activatcd PBMC with human rccombinant IL-2 induced a decrcase in the mean fluorescencc
of IL-2R highly positivc lymphoblastcs by about by 20% in one monkey and 29% in the second
one. The dccrcase in the mcan fluorcsccnce is probably due to IL-2R internalization and, therefore,
is an indirect argument for the spccificity of the anti-CD25 antiLxxty.
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Discussion
Human T-cell proliferation involves IL-1 production by monocytes, followed by autocrine IL-2
secretion by a T-lymphocyte subpopulation, and IL-2R expression on T-lymphocytes undergoing
proliferation / differentiation (10). In the present report, we showed that IL- 1 and IL-2 secretion in
vitro by P13MC from rhesus monkey and T-lymphocyte expression of IL-2R can be detected b'y
MAbs directed against the corresponding human antigens. Moreover, IL-1 synthesis and secretion
and, to a lesser extent, IL-2 synthesis, were inducible by PMA, and PHA potentiated the effect of
PMA. However, the optimal concentration of PMA is much lower in the rhesus monkey than in
humans. Unlike the human case, PBMC in the presence of PHA alone produced only a small
amount of IL-2. Nevertheless, PHA-induced T-lymphocyte proliferation, evidenced by [3HI
thymidine incorporation (27), was similar to what is observed in humans. Therefore, the IL-2
production might be underestimated if the anti-IL-2 antibody used has a lower affinity with the
macaque IL-2. The cross-reactivity for these cytokines has also been demonstrated with commercial
sandwich immunoassays showing that two opposite epitopes are recognized by anti-human MAbs.
Because these ELISA assays are sandwich assays and because two different tests were used
successfully for each cytokine, four epitopes have therefore been recognized on each molecule.
Despite these data we can not exclude cross-reactivities with other proteins. The IL-2R was
expressed on some T-lymphocytes and was enhanced in PHA or PMA-stimulated cells with a time-
dependent increase similar to what is observed in humans. The incubation of lymphocytes with IL-
2 decreased the amount of labeling with our antibody against the IL-2R. This is due to the
internalization of the IL-2R and can be considered as an additional argument for the specificity of
the antibody. In contrast to rhesus monkeys and humans, T-lymphocytes from Japanese monkeys
(Macaca fuscata) respond less to PHA as shown by [3H] thymidine incorporation and they also
express IL-2R to a lesser extent (15). Nevertheless, in our experiment, not all anti-lL-2R MAbs
studied stained-activated T lymphocytes (unpublished results), demonstrating that some epitopes of
the receptor are wcakly or not recognized by certain anti-human MAbs.
Despite the fact that a number of anti-human MAbs have been used to characterise rhesus
monkcy surfacc antigens (14, 17, 21, 25), the interspecies similarities concerning cytokine
secretion by and rcgulation of moncytc and lymphocyte functions are known poorly. Lymphokines
such as interferon-gamma and tumor necrosis factor-alpha have been identified in several rhesus
monkcv tissues on frozen sections (25) and human MAbs directed against these lymphokines had
immunosupressive effects in vivo (24). Human 13 cell growth factor (BCGF) or human
recombinant IL-4 were found to be stimulatory for macaque splenic B cells (3, 11) and recombinant
human intefleukin-3 and granulocyte/macrophage colony-stimulating factor promotes peripheral
blexx.t hcmatopoietic progenitor cells in thc rhcsus monkey (8). Messenger RNA from IL-2, IL-4,
IL-5, 1L-2R, and interferon-gamma could be detected with human eDNA probes in T cells from
rhesus monkey intestinal lamina propria (11). Additionally, we have recently shown that interferon-
gamma production can be induced and quantified with a human enzyme immunoassay (23).
Thercfore, a profile of rhesus monkey cytokine activities is now emerging.
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